ARTL — ARTELO BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1621221 ·
Last close
$3.26
Market Cap
$1.79M
52W High
$179.19
52W Low
$3.19
ADV30
975,816
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,505,000 | -2,427,000 | 6,459,000 | 4,198,000 | 1,462,000 |
| Mar 2026 | 0 | — | -2,689,000 | -2,958,000 | 12,518,000 | 10,273,000 | 5,846,000 |
| Dec 2025 | 0 | — | -2,786,000 | -4,166,000 | 2,801,000 | 600,000 | 4,073,000 |
| Sep 2025 | 0 | — | -3,089,000 | -3,120,000 | 4,267,000 | 1,720,000 | 4,900,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,114,000
Investing CF
$-62,000
Financing CF
$17,727,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-45.29
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-65,973,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-13,064,000
Pretax Income TTM
$-13,465,000
Interest Exp TTM
$401,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,404,000 | -12,879,000 | 2,801,000 | 4,073,000 | -1,272,000 | -8,520,000 |
| Dec 2024 | 0 | -10,108,000 | -9,826,000 | 4,698,000 | 1,841,000 | 2,857,000 | -8,350,000 |
| Dec 2023 | 0 | -9,930,000 | -9,289,000 | 13,043,000 | 1,291,000 | 11,752,000 | -8,207,000 |
| Dec 2022 | 0 | -10,287,000 | -10,083,000 | 20,424,000 | 1,021,000 | 19,403,000 | -8,008,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-13,465,000
OpCashFlow TTM
—
Assets (Latest)
$12,518,000
Forward EPS
$-0.88
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LABT | Lakewood-Amedex Biotherapeutics Inc. | $1.85M | $0.78 | — |
| VBIO | Valion Bio, Inc. | $1.90M | $2.14 | — |
| AGNPF | Grey Matters Health Inc. | $1.63M | $0.30 | — |
| RNAZ | Transcode Therapeutics, Inc. | $1.97M | $1.86 | — |
| TCRT | Alaunos Therapeutics, Inc. | $2.00M | $0.79 | — |
News headlines (Yahoo Finance, 1h cache)
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
2026-10-07 12:48 · Yahoo
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
2026-09-23 11:33 · Yahoo
Artelo Biosciences Announces Reverse Stock Split
2026-08-27 12:00 · Yahoo
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
2026-08-17 12:52 · Yahoo
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
2026-08-13 12:00 · Yahoo
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
2026-07-22 12:39 · Yahoo
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
2026-07-16 12:48 · Yahoo
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
2026-07-14 12:47 · Yahoo
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
2026-07-13 13:02 · Yahoo
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
2026-07-01 12:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.